Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AMTI NASDAQ:CARA NASDAQ:OLMA NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.59+3.2%$1.41$1.05▼$5.17$166.75M0.381.20 million shs1.27 million shsAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/ACARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4123,271 shs237,144 shsOLMAOlema Pharmaceuticals$4.85-2.8%$4.61$2.86▼$16.62$341.42M1.9821,141 shs382,919 shsTBPHTheravance Biopharma$11.46-1.1%$10.28$7.44▼$11.82$579.52M-0.02266,403 shs120,555 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+3.25%+10.03%+5.30%+38.26%+25.20%AMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%+8.57%+55.01%OLMAOlema Pharmaceuticals-2.81%+10.23%+15.20%+28.65%-58.23%TBPHTheravance Biopharma-1.12%+2.46%+6.80%+36.43%+29.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.6645 of 5 stars3.62.00.00.02.61.70.6AMTIApplied Molecular TransportN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics0.3713 of 5 stars0.00.00.04.20.60.80.0OLMAOlema Pharmaceuticals1.7966 of 5 stars3.51.00.00.00.02.50.6TBPHTheravance Biopharma1.5254 of 5 stars3.30.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71448.07% UpsideAMTIApplied Molecular Transport 0.00N/AN/AN/ACARACara Therapeutics 0.00N/AN/AN/AOLMAOlema Pharmaceuticals 3.00Buy$24.50405.15% UpsideTBPHTheravance Biopharma 2.67Moderate Buy$16.6044.85% UpsideCurrent Analyst Ratings BreakdownLatest CARA, OLMA, TBPH, AMTI, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$6.006/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$24.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M9.20N/AN/A$1.44 per share1.10AMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/ACARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ATBPHTheravance Biopharma$64.38M8.90N/AN/A$3.57 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)AMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AOLMAOlema Pharmaceuticals-$129.47M-$2.01N/AN/AN/AN/A-42.31%-38.32%8/5/2025 (Estimated)TBPHTheravance Biopharma-$56.42M-$1.18N/A32.74N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)Latest CARA, OLMA, TBPH, AMTI, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ACRSAclaris Therapeutics-$0.14N/AN/AN/A$1.34 millionN/A8/5/2025Q2 2025OLMAOlema Pharmaceuticals-$0.44N/AN/AN/AN/AN/A8/4/2025Q2 2025TBPHTheravance Biopharma-$0.12N/AN/AN/A$16.04 millionN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAMTIApplied Molecular TransportN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06AMTIApplied Molecular TransportN/A4.994.99CARACara TherapeuticsN/A4.774.71OLMAOlema PharmaceuticalsN/A15.2215.22TBPHTheravance BiopharmaN/A4.774.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AMTIApplied Molecular Transport41.79%CARACara Therapeutics44.66%OLMAOlema Pharmaceuticals91.78%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%AMTIApplied Molecular Transport15.90%CARACara Therapeutics3.10%OLMAOlema Pharmaceuticals16.36%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableOLMAOlema Pharmaceuticals7068.42 million57.23 millionOptionableTBPHTheravance Biopharma11050.00 million46.55 millionOptionableCARA, OLMA, TBPH, AMTI, and ACRS HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst UpgradeJune 27, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG ResearchJune 27, 2025 | marketbeat.comTBPH Theravance Biopharma, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPAJune 26, 2025 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" RatingJune 21, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?June 17, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from AnalystsJune 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at Jones TradingJune 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - What's Next?June 17, 2025 | marketbeat.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of StockJune 5, 2025 | insidertrades.comTBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock RisesJune 3, 2025 | zacks.comTheravance Shares Rise Premarket on Sale of Trelegy RoyaltiesJune 2, 2025 | marketwatch.comTheravance hands off the last of its Trelegy royalties to GSK for $225MJune 2, 2025 | fiercepharma.comFTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 MillionJune 2, 2025 | prnewswire.comTheravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and AmpreloxetineMay 21, 2025 | investing.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 13, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)May 11, 2025 | theglobeandmail.comEarnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecastMay 10, 2025 | uk.investing.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, OLMA, TBPH, AMTI, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.59 +0.05 (+3.25%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$1.62 +0.03 (+1.64%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Applied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Olema Pharmaceuticals NASDAQ:OLMA$4.85 -0.14 (-2.81%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$4.82 -0.03 (-0.72%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Theravance Biopharma NASDAQ:TBPH$11.46 -0.13 (-1.12%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$11.46 0.00 (0.00%) As of 07/10/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
